These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 28919989)

  • 61. A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab.
    Fessas P; Lee H; Ikemizu S; Janowitz T
    Semin Oncol; 2017 Apr; 44(2):136-140. PubMed ID: 28923212
    [TBL] [Abstract][Full Text] [Related]  

  • 62. T cell effects and mechanisms in immunotherapy of head and neck tumors.
    Xiang Y; Gong M; Deng Y; Wang H; Ye D
    Cell Commun Signal; 2023 Mar; 21(1):49. PubMed ID: 36872320
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinical implications of T cell exhaustion for cancer immunotherapy.
    Chow A; Perica K; Klebanoff CA; Wolchok JD
    Nat Rev Clin Oncol; 2022 Dec; 19(12):775-790. PubMed ID: 36216928
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Heterogeneity and clonality of kidney-infiltrating T cells in murine lupus nephritis.
    Smita S; Chikina M; Shlomchik MJ; Tilstra JS
    JCI Insight; 2022 Apr; 7(8):. PubMed ID: 35271505
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times.
    Bailly C; Thuru X; Quesnel B
    NAR Cancer; 2020 Mar; 2(1):zcaa002. PubMed ID: 34316682
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Investigating Macrophages Plasticity Following Tumour-Immune Interactions During Oncolytic Therapies.
    Eftimie R; Eftimie G
    Acta Biotheor; 2019 Dec; 67(4):321-359. PubMed ID: 31410657
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition.
    Newton JM; Hanoteau A; Liu HC; Gaspero A; Parikh F; Gartrell-Corrado RD; Hart TD; Laoui D; Van Ginderachter JA; Dharmaraj N; Spanos WC; Saenger Y; Young S; Sikora AG
    J Immunother Cancer; 2019 Aug; 7(1):216. PubMed ID: 31409394
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy.
    Hanoteau A; Newton JM; Krupar R; Huang C; Liu HC; Gaspero A; Gartrell RD; Saenger YM; Hart TD; Santegoets SJ; Laoui D; Spanos C; Parikh F; Jayaraman P; Zhang B; Van der Burg SH; Van Ginderachter JA; Melief CJM; Sikora AG
    J Immunother Cancer; 2019 Jan; 7(1):10. PubMed ID: 30646957
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.
    Pol JG; Lévesque S; Workenhe ST; Gujar S; Le Boeuf F; Clements DR; Fahrner JE; Fend L; Bell JC; Mossman KL; Fucikova J; Spisek R; Zitvogel L; Kroemer G; Galluzzi L
    Oncoimmunology; 2018; 7(12):e1503032. PubMed ID: 30524901
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Antigen-specificity and DTIC before peptide-vaccination differently shape immune-checkpoint expression pattern, anti-tumor functionality and TCR repertoire in melanoma patients.
    Palermo B; Franzese O; Donna CD; Panetta M; Quintarelli C; Sperduti I; Gualtieri N; Foddai ML; Proietti E; Ferraresi V; Ciliberto G; Nisticò P
    Oncoimmunology; 2018; 7(12):e1465163. PubMed ID: 30524882
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy.
    García-Martínez E; Smith M; Buqué A; Aranda F; de la Peña FA; Ivars A; Cánovas MS; Conesa MAV; Fucikova J; Spisek R; Zitvogel L; Kroemer G; Galluzzi L
    Oncoimmunology; 2018; 7(6):e1433982. PubMed ID: 29872569
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cyclophosphamide plus tumor necrosis factor-alpha chemoimmunotherapy cured mice: life-long immunity and rejection of re-implanted primary lymphoma.
    Ehrke MJ; Verstovsek S; Krawczyk CM; Ujházy P; Zaleskis G; Maccubbin DL; Mihich E
    Int J Cancer; 1995 Nov; 63(3):463-71. PubMed ID: 7591249
    [TBL] [Abstract][Full Text] [Related]  

  • 73. CD8
    Kurachi M
    Semin Immunopathol; 2019 May; 41(3):327-337. PubMed ID: 30989321
    [TBL] [Abstract][Full Text] [Related]  

  • 74. CD8
    Farhood B; Najafi M; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cyclophosphamide treatment regulates the balance of functional/exhausted tumor-specific CD8
    Hanoteau A; Henin C; Svec D; Bisilliat Donnet C; Denanglaire S; Colau D; Romero P; Leo O; Van den Eynde B; Moser M
    Oncoimmunology; 2017; 6(8):e1318234. PubMed ID: 28919989
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cyclophosphamide treatment induces rejection of established P815 mastocytoma by enhancing CD4 priming and intratumoral infiltration of P1E/H-2K(d) -specific CD8+ T cells.
    Rahir G; Wathelet N; Hanoteau A; Henin C; Oldenhove G; Galuppo A; Lanaya H; Colau D; Mackay CR; Van den Eynde B; Moser M
    Int J Cancer; 2014 Jun; 134(12):2841-52. PubMed ID: 24249003
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells.
    Bae EA; Seo H; Kim BS; Choi J; Jeon I; Shin KS; Koh CH; Song B; Kim IK; Min BS; Han YD; Shin SJ; Kang CY
    Cancer Res; 2018 Sep; 78(18):5315-5326. PubMed ID: 30012672
    [TBL] [Abstract][Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.